A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 May 2014
Price : $35 *
At a glance
- Drugs RDC 5 (Primary)
- Indications Neurological disorders; Osteoporosis
- Focus Pharmacokinetics
- Sponsors Chronos Therapeutics
- 11 Mar 2014 Status changed to completed as reported by ClinicalTrials.gov.
- 14 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Jan 2014 New trial record